Date Mailed:

OCT 2 2 2001

Aplication #: 09/896, 139

Sheet 1 of 11

FORM 1449* \ 7.

THEORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USUI

Application Number

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: 1645 77724

			U.S. PATENT DOCUMEN	NTS		300/290
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
RIR	4,224,179 (456)	09/23/1980	Schneider			
RR	4,231,877 (457)	11/04/1980	Yamauchi et al.			
RR	4,235,871 (447)	11/25/1980	Papahadjopoulos			
RR	4,247,411 (448)	01/27/1981	Vanlerberghe et al.		-	
1818	4,394,448 (458)	07/19/1983	Szoka, Jr. et al.		-	
KR	4,399,216 (459)	08/16/1983	Axel et al.			
1317	4,522,811 (707)	06/11/1985	Eppstein et al.			
RK	4,616,088 (688)	10/07/1986	Ryono et al.		_	
146	4,636,491 (598)	01/13/1987	Bock et al.			
RR	4,665,193 (706)	05/12/1987	Ryono et al.			
1515	4,668,770 (99)	05/26/1987	Boger et al.			
RR	4,673,567 (460)	06/16/1987	Jizomoto			
195	4,676,980 (461)	06/30/1987	Segal et al.		_	
188	4,736,866 (474)	04/12/1988	Leder et al.			
RP	4,749,792 (597)	06/07/1988	Natarajan et al.			:
1213	4,753,788 (462)	06/28/1988	Gamble			
RR	4,814,270 (463)	03/21/1989	Piran		 .	
RR	4,816,567 (464)	03/28/1989	Cabilly et al.		· ·	
1915	4,870,009 (465)	09/26/1989	Evans et al.			
M	4,880,781 (13)	11/14/1989	Hester, Jr. et al.			
NN	4,897,355 (466)	01/30/1990	Eppstein et al.			
विर	5,010,182 (467)	04/23/1991	Brake et al.		_	
138	5,142,056 (590)	08/25/1992	Kempe et al.			
1313	5,145,684 (846)	09/08/1992	Liversidge et al.			
15/5	5,162,538 (17)	11/10/1992	Voges et al.			
RR	5,175,281 (594)	12/29/1992	McCall et al.			
RR	5,250,565 (444)	10/05/1993	Brooks et al.			

U.S. PATENT DOCUMENTS

EXAMINER / (aymy)	

DATE CONSIDERED

6-000

Sheet 2 of 11

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USUI Application Number:

09/895,871

33. 33.

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: 1645

9 200 1 200

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING TE IF APPROPRIATE
irr	5,364,934 (468)	11/15/1994	Drayna et al.			
RR	5,374,652 (446)	12/20/1994	Buzzetti et al.			
NSIS	5,376,542 (469)	12/27/1994	Schlegal		_	
RP	5,387,742 (177)	02/07/1995	Cordell			
156	5,441,870 (189)	08/15/1995	Seubert et al.		_	
19%	5,461,067 (599)	10/24/1995	Norbeck et al.			
_ RR	5,475,138 (556)	12/12/1995	Pal et al.			
RR	5,481,011 (847)	01/02/1996	Chen et al.			
136	5,482,947 (838)	01/09/1996	Talley et al.			
PR	5,502,061 (591)	03/26/1996	Hui et al.			
1365	5,502,187 (595)	03/26/1996	Ayer et al.			·
RR	5,508,294 (837)	04/16/1996	Vazquez et al.			
Rv?	5,510,349 (853)	04/23/1996	Talley et al.		_	
RR	5,510,388 (703)	04/23/1996	Vazquez et al.			
Λυγ	5,516,784 (640)	05/14/1996	Bennett et al.		_	
NSIS.	5,521,219 (850)	05/28/1996	Vazquez et al.			
RR	5,545,640 (642)	08/13/1996	Beaulieu et al.			•
155	5,593,846 (201)	01/14/1997	Schenk et al.	7		
RR	5,602,175 (542)	02/11/1997	Talley et al.	<u></u> -		
RIR	5,602,169 (445)	02/11/1997	Hewawasam et al.		· · · · · · · · · · · · · · · · · · ·	
MR	5,604,102 (202)	02/18/1997	McConlogue et al.			
158	5,610,190 (638)	03/11/1997	Talley et al.			
RR	5,612,486 (185)	03/18/1997	McConlogue et al.			
RR	5,625,031 (470)	04/29/1997	Webster et al.			
195	5,631,405 (554)	05/20/1997	Pal et al.			
RR	5,639,769 (836)	06/17/1997	Vazquez et al.			
- TT-	5,648,511 (704)	07/15/1997	Ng et al.			
1965	5,663,200 (18)	09/02/1997	Bold et al.			
RIP	5,708,004 (536)	01/13/1998	Talley et al.			ş

		/	
EXAMINER	Raymuy	DATE CONSIDERED	6-10-0

FORM 1449*

INFORMATION PISCLOSURE ATEMENT

IN AN APPLICATION (Use several sheets if necessary)

13615.21USU1

Docket Number:

Application Num 09/895,871

Applicant: FANG ET AL. Filing Date: JUNE 29, 2001

Group Art Unit: 16 5 62 6

						8 9
R	5,720,936 (186)	02/24/1998	Wadsworth et al.			00/2900
KR	5,721,130 (184)	02/24/1998	Seubert et al.			
1515	5,733,882 (29)	03/31/1998	Carr et al.		_	
RR	5,744,346 (182)	04/28/1998	Chrysler et al.			
RR	5,753,652 (711)	05/19/1998	Fässler et al.		_	
KIS	5,760,064 (851)	06/02/1998	Vazquez et al.			
RR	5,760,076 (548)	06/02/1998	Vazquez et al.			
1513	5,766,846 (171)	06/16/1998	Schlossmacher et al.		~	
1415	5,807,870 (652)	09/15/1998	Anderson et al.			
<i>{B}</i>	5,807,891 (19)	09/15/1998	Bold et al.			
rèss	5,811,633 (176)	09/22/1998	Wadsworth et al.			
RR	5,827,891 (639)	10/27/1998	Dressman et al.		_	
RR	5,830,897 (653)	11/03/1998	Vazquez et al.		_	
195	5,831,117 (547)	11/03/1998	Ng et al.			
1565	5,847,169 (645)	12/08/1998	Nummy et al.			
RR	5,849,911 (535)	12/15/1998	Fässler et al.		-	
RR	5,850,003 (705)	12/15/1998	McLonlogue et al.	_		
RD	5,863,902 (428)	01/26/1999	Munoz et al.			
RR	5,872,101 (429)	02/16/1999	Munoz et al.			
RR	5,877,015 (710)	03/02/1999	Hardy et al.			
RP	5,877,399 (178)	03/02/1999	Hsiao et al.			
IPP	5,912,410 (418)	06/15/1999	Cordell			
RP.	5,922,770 (543)	07/13/1999	Peschke et al.			
VAR	5,935,976 (91)	08/10/1999	Bold et al.			
177	5,942,400 (181)	08/24/1999	Anderson et al.			
RR	5,962,419 (434)	10/05/1999	McDonald et al.			
RR	5,965,588 (686)	10/12/1999	Vazquez et al.		_	
RR.	6,001,813 (131)	12/14/1999	Gyorkos et al.			
1317	6,013,658 (16)	01/11/2000	Lau et al.			
RIZ	6,022,872 (644)	02/08/2000	Vazquez et al.			· · · · · · · · · · · · · · · · · · ·
917	6,045,829 (538)	04/04/2000	Liversidge et al.			
		-			•	

and not considered. Include copy of this form for next communication to the Applicant.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance

FO	RM 1	449*
LOI	VIVI I	447

INFORMATION DISCLOSURE STA

Docket Number: 13615.21USU1

Application Nur

09/895,871

IN AN APPLICATION (Use several sheets if necessary) Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit:- 1645

RR	6,051,684 (427)	04/18/2000	McDonald et al.			99	
134	6,060,476 (637)	05/09/2000	Vazquez et al.	-	,		
RR	6,150,344 (685)	11/21/2000.	Carroll et al.				
ISIS	6,153,652 (191)	11/28/2000	Wu et al.				
1212	6,191,166 B1 (50)	02/20/2001	Audia et al.				
187	6,221,670 B1 (355)	04/24/2001	Cordell et al.				
		FO	REIGN PATENT DOCUMEN	TS			
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	МО
RR	0 036776 A2 (471)	09/30/1981	Europe				
RR	0 073 657 B1 (476)	03/09/1983	Europe		_		
<i>(</i> ?1?	0 117 060 A2 (472)	08/29/1984	Europe				
RR	0 117 058 B1 (473)	08/29/1984	Europe				
1315	0 173 441 A1 (557)	05/03/1986	Europe		_		
1515	0 209 897 A2 (90)	91/2/8/1987	Europe				
V217	0 212 903 B1 (100)	03/04/1987	Europe				
193	DE 3610593 A1 (98)	10/01/1987	Germany		_		
RR	0 264 106 B1 (101)	04/20/1988	Europe				
BJS.	DE 3721 855 A1 (93)	09/22/1988	Germany		_		
AR.	0 274 259 A2 (89)	07/13/1988	Europe		<u> </u>		
RR	2 203 740 A (544)	10/25/1988	UK	-	. —		
561	2 211 504 A (475)	Ó7/05/1989	UK .		_		i
RP.	0 320 205 A2 (102)	06/14/1989	Europe				
13R	0 337 714 (8)	10/18/1989	Europe				,
1515	0 362 179 A2 (449)	04/04/1990	Europe		_		
RR	0 372 537 A2 (96)	06/13/1990	Europe		_		
1515	0 437 729 A2 (21)	971/24/1991	Europe				
\ RR	DE 40 03 575 AT	08/08/1991	Germany				<u></u>
1317	0 609 625 A1 (567)	08/10/1994	Europe				
13/5	0 652 009 A1 (709)	05/10/1995	Europe				
RV	7-126286 (97)	05/16/1995	Japan				1

EXAMINER

DATE CONSIDERED

6-10-02

14400-1:11

FORM 1449*

INFORMATION DISC

Docket Number: 13615.21USU1

Application Number:

09/895,871

IN AN APPLICATION (Use several sheets if necessary) Applicant: FANG ET AL. Filing Date: JUNE 29, 2001

Group Art Unit: 4645 1624

		/					
RR	WO 87/02986 (551)	65/21/1987	PCT				
RR	WO 87/04349 (10)	07/30/1987	PCT				
RR	WO 87/05330 (454)	99/11/1987	PCT				
ISIS	WO 89/00161 (15)	01/12/1989	PCT '				
RR	WO 89/01488 (12)	02/23/1989	PCT				
RR	WO 89/05859 (453)	06/29/1989	PCT				
138	WO 90/13646 (452)	1/15/1990	PCT		_		
RR	WO 91/00360 (451)	01/10/1991	PCT				•
RR	WO 92/00750 (537)	01/23/1992	PCT				
RY?	WO 92/17490 (14)	10/15/1992	PCT		_		
RR	WO 92/20373 (455)	11/26/1992	PCT				
RR	WO 93/02057 (11)	02/04/1993	PCT				
RP &	WO 93/08829 (450)	05/13/1993	PCT		_		
RR	WO 93/17003 (7)	09/02/1993	PCT				
mx.	WO 94/04492 (848)	03/03/1994	PCT				
PR X	WO 95/06030 (839)	03/02/1995	PCT				
RR #	WQ 97/30072 (22)	08/21/1997	PCT				
RRX	WO 98/22597 (170)	05/28/1998	PCT		<u> </u>		
RP &	WO 98/29401 (562)	07/09/1998	PCT			-	
RŘ X	WQ 98/33795 (546)	08/06/1998	PCT	·		. ::	
RR	WO 98/50342 (\$50)	11/12/1998	PCT		(•
RR (a	WO 99/41266 (568)	08/19/1999	PCT -		1		
RR 🗞	WO 99/54293 (635)	10/28/1999	PCT			• •	
RR &	WO 00/17369 (169)	03/30/2000	PCT . Addition lives	·1021 114 0	. v. <u> </u>		
1315	WO 00/47618 (364)	08/17/2000	PCT				-
RR	WO 00/56335 (314)	09/28/2000	PCT		_		
13.2	WO 00/61748 (302)	10/19/2000	PCT		_		
RP	WO 00/69262 (272)	11/23/2000	PCT				
RP	WO 00/77030 (256)	12/21/2000	PCT	. —	. ——		
P/7	WO 01/00663 (159)	01/04/2001	PCT				
RR 4	_p WO 01/00665 A2 (20)	01/04/2001	PCT	_			
V		,					

EXA	M	NE	R
-----	---	----	---

DATE CONSIDERED

6-10-03

Date	Mailed:	

Sheet 6 of 11

Filing Date: JUNE 29, 2001

Group Art Unit: 1645-1624

	•	
FORM 1449* INFORMATION DISCLOSIONESTATEMENT	Docket Number: 13615.21USU1	Application Number: 09/895,871
IN AN APPLICATION	Applicant: FANG ET AI	L.

(Use several sheets if necessary)

* BLS	WO 01/10387 A2 (443)	02/15/2001	PCT						
RR	WO 01/19797 A2 (381)	03/22/2001	PCT						
ARD	,WO 01/23533 A2 (289)	04/05/2001	PCT		_				
, BK	WO 01/29563 A1 (479)	WO 01/29563 A1 (479) 204/26/2001 PCT							
RR	WO 01/51659 A2 (790)	07/19/2001	PCT						
1									
				-					
	ОТН	ER DOCUMEN	TS (Including Author, Title, Dat	te, Pertinent Pag	ges, Etc.) -				
RR	Abbenante,	et al., Biochemic	al and Biophysical Research Co	mmunications,	2000, 268,pp. 13313:	5			
	Inhibitors of	fβ-Amyloid For	nation Based on theβ-Secretase	Cleavage Site [439]				
RR	Design and	Alterman et al., J. Med. Chem, 1998, 41, 3782-3792 Design and Synthesis of New Potent C ₂ -Symmetric HIV-1 Protease Inhibitors. Use of L-Mannaric Acid as a Peptidomimetic Scaffold [868]							
RR		Amblard et al., J. Med. Chem., 1999, 42:20, pp. 4193-4201 Synthesis and Characterization fo Bradykinin B ₂ Receptor Agonists Containing Constrained Dipeptide Mimics [730]							
RR	1	Arrowsmith et al., Tetrahedron Letters, 1987, 28:45, pp. 5569-5572 Amino-Alcohol Dipeptide Analogues: A Simple Synthesis of a Versatile Isostere for the Development of Proteinase Inhibitors [584]							
IZR	Highly Disa	Askin et al., The Journal of Organic Chemistry, 1992, 57:10, pp. 2771-2773 Highly Disastrous Alkylations of Chiral Amide Enolates: New Routes to Hydroxyethylene Dipeptide Isostere Inhibitors of HIV-1 Protease [561]							
KR			, <u>199</u> 3, 23(22), pp. 3149-3155 on of Nitriles to Amides with Ba	sic Ur c a-Hydro	gen Peroxide Adduc	t [874]	-		
RN	I	tective Groups in of N-H Bonds ar	Organic Chemistry, 1976, Chp	t. 2, pp. 43-93					
RR		Basu et al., Tetrahedron Letters, 1998, 39, pp. 3005-3006 Efficient Transformation of Nitrile into Amide under Mild Condition [881]							
RR	1 1 .	al., <i>Synlett</i> , 1993, sis of Novel HIV	, 9, pp. 703-704 7-Protease Inhibitors via Silica G	el Asisted Add	ition of Amines to Ep	ooxides [744]			
RR		, Journal of Phatical Salts [735]	rmaceutical Sciences, 1/1977, 66	5:1, pp. 1-19					
RR	1 :	nic Syntheses, Come [883]	ollective Vol. 2, pp. 312-315	•			·		
RP	1 1		al of Biological Chemistry, 2001	•		ursor Protein [4	193]		

	\sim	/	`		
EXAMINER	7	1	aynys	DATE CONSIDERED	6-10-03



FORM 1449*

INFORMATION DISCLOSURE SETTEMENT
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USU1 Application Number:

09/895,871

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: 1645-162-/

RR	Bose et al., Synth. Comm., 1997, 27(18), pp. 3119 - 3123 A Facile Hydration of Ntiriles by Dimethyldioxirane [876]
RR	Calderwood et al., <i>Tetrahedron Letters</i> , 1997, 38:7, pp. 1241 - 1244 Organocerium Reactions of Benzamides and Thiobenzamides: A Direct Synthesis of Tertiary Carbinamines [741]
RR	Chen et al., Tetrahedron -Mannaric Acid Letters, 1997, 38:18, pp. 3175 - 3178 A Practical Method for the Preparation of α'-Chloroketones of N-Carbamate Protected-α-Aminoacids [885]
1313	Ciganek, J. Org. Chem., 1992, 57:16, pp. 4521 - 4527 Tertiary Carbinamines by Addition of Organocerium Reagents to Nitriles and Ketimizs [721]
1315	Citron et al., <i>Nature</i> , 1992, 360:6405, pp. 672-674 Mutation of the β-amyloid Precursor Protein in Familial Alzheimer's Disease Increases β-Protein Production [722]
RK	Cushman et al., J. Med. Chem., 1997, 40:15, pp. 2323 - 2331 Synthesis of Analogs of 2-Methoxyestradiol with Enhanced Inhibitory Effects on Tubulin Polymerization and Cancer Cell Groth [734]
RR	Deno, et al., J. Am. Chem. Soc., 1970, 92:7, pp. 3700 - 3703 Protonated Cyclopropane Intermediates in the Ractions of Cyclopropanecarboxylic Acids [727]
RR	Diedrich et al., Tetrahedron Letters, 1993, 34:39, pp. 6169-6172 Stereoselective Synthesis of A Hydroxyethylene Dipeptide Isostere [559]
<i>ખ્ટે</i> લ્ટ	Diercks et al., J. Am. Chem. Soc., 1986, 108:11, pp. 3150-3152 Tris(benzocyclobutadieno)benzene, the Triangular [4]Phenylene with a Completely Bond-Fixed Cyclohexatriene Ring: Cob Catalyzed Synthesis from Hexaethynlbenzene and Thermal Ring Opening to 1,2:5,6:9, 10-Tribenzo-3,4,7,8,11,12 hexadehydro[12]-annulene [728]
RR	Dovey et al., Journal of Neurochemistry, 2001, 76, pp. 173-181 Functional Gamma-Sec]retase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain [396
RR	Dragovich et al., Journal of Medicinal Chemistry, 1929, 42:7, pp. 1203-1212 Structure-Based Desing, Synthesis, and Biological Evaluation of Irreverible Human Rhinovirus 3C Protease Inhibitors [553]
145	Emilien, et al., Neurological Review, 2000, 57, pp. 454-459 Prospects for Pharmacological Intervention in Alzheimer Disease [723]
RR	Felman et al., J. Med. Chem. 1992, 35:7, pp. 1183-190 Synthesis and Antiulcer Activity of Novel 5-(2-Ethenyl Substituted)-3(2H) furanones [724]
RR	Games et al., Letters to Nature, 2/9/1995, 373:6514, pp. 523-527 Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717FB-amyloid Precursor Protein [441]
RR	Gao et al., Tetrahedron Letters, 1994, 50:4, pp. 979-988 Asymmetric Hetero Diels-Alder Reaction Catalyzed by Stable and Easily Prepared CAB Catalysts [882]
1513	Getman et al., J. Med. Chem., 1993, 36:2, pp. 288-291 Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere [732]
1717.	Ghosh et al., J. Am. Chem. Soc., 2000, -122, pp. 3522-3523 Design of Potent Inhibitors for Human Brain Memapsin 2 β-Secretase). [588]
1315	Ghosh et al., J. Med. Chem., 1993, 36, pp. 2300-2310. Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel P ₃ -Ligands [869]

	2-0-	1	
EXAMINER	1 Clary	DATE CONSIDERED	6-10-03
	1/		

FORM 1449* INFORMATION DISCLOSURE ST EMENT

13615.21USU1 Applicant: FANG ET AL.

Docket Number:

Application Number

09/895,871

(Use several sheets if necessary)

Filing Date: JUNE 29, 2001

Group Art Unit: 1643

	2
1312	Gould, international Journal of Pharmaceutics, 1986, 33:1-3, pp. 201 - 217 Salt Selection for Basic Drugs [566]
RR	Greene et al., Protective Groups in Organic Synthesis: 2nd Ed., 1991, Chpt. 7, pp. 309-405 Protection for the Amino Group [747]
KR	Greene, Protective Groups in Organic Synthesis, 1981, Chpt. 7, pp.218-287 Protection for the Amino Group [719]
RR	Hardy, Nature Genetics, 1992, 1, pp. 233234 Framing β-Amyloid [725]
1312	Heck, <u>Palladium Reagents in Organic Syntheses</u> , 1985, Chpt. 8.2, pp. 342-365 Carbonylatin of Aromatic Compounds to Acids, Acid Derivatives, Aldehydes and Ketones [870]
ારાર	Henning, Organic Synthesis Highlights II, 1995, pp. 251 - 259 A. Synthetic Routes to Different Classes of Natural Products and Analogs Thereof Synthesis of Hydroxyethylene Isoteric Dipeptides [565]
RR	Hon et al., Heterocycles, 1990, 31:10, pp. 17451750 The Studies of Metal Ion Catalyzed Carbon-Hydrogen Insertion of α-Alkoxy-α'-Diazoketones Derived from Mandelic and Lactic Acids [539]
1212	Hong et al., Science, 2000, 290:5489, pp. 150-153 Structure of the Protease Domain of Memapsin 2 (3-Secretase) Complexed with Inhibitor [440]
RR	Hussain et al., Molecular and Cellular Neuroscience, 1999, 14, pp. 419-427 Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase [726]
RR	Kabalka et al., Synth. Comm., 1990, 20(10), pp. 14451451 The Transformation of Nitriles into Amides [875]
RR	Kaldor et al., Bioorganic and Medicinal Chemistry Letters, 1995, 5:7, pp. 721-726 Isophthalic Acid Derivatives: Amino Acid Surrogates for the Inhibition of HIV-1 Protease [587]
1515	Kang et al., Nature, 1987, 325:6106, pp. 733736 The Precursor of Alzheimer's Disease Amyloid A4 Portein Resembles a Cell-Surface Receptor [505]
RR	Kitaguchi et al., Nature, 2/11/1988, 331:6156, pp. 530-532 Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity [736]
1515	Klumpp et al., J. Am. Chem. Soc., 1979, 101:23 Lithiation of Cyclopropylcarbinols [871]
RR	Lakouraj et al., Indian Journal of Chemistry, 1999, 38B, pp. 974-975 Selective Conversion of Nitriles to Amides by Amberlyst A-26 Supported Hydroperoxide [879]
RP	Larock, Comprehensive Organic Transformations, 1986, Chpt 4, pp. 972-985 Carboxylic Acids to Amides [555]
KIG	Li et al., Nature, 2000, 405, pp. 689-694 Photoactivated V-secretase Inhibitors Directed to the Active Site Covalently Label Presentilin 1 [24]
RN	Li et al., Nature, 2000, 405:6787, pp. 689694 Photoactivated Gamma-Secretase Inhibitors Directed to the Active Site Covalently Label-Presentlin-1. [585]

	·O a		
EXAMINER	Riconstant	DATE CONSIDERED	6-10-03

FORM 1449*

INFORMATION DISCLOSURE TATEMENTS OF TRADENTS

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USU1

Application Number:

09/895,871

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: -1645 1674

RR	Lin et al., PNAS, 2000, 97:4, pp. 14561460 Human Aspartic Protease Memapsin 2 Cleaves theβ-Amyloid Precursor Protein [687]
1515	Luly et al., Journal of Organic Chemistry, 1987, 52:8, pp. 14871492 A Synthesis of Protected Aminoalkyl Epoxides from Alpha Amino Acids [558]
RR	Luo et al., Nature Neuroscience, 3/2001, 4:3, pp. 231-232 Mice Deficient in BACE1, the Alzheimer's β-secretase, have Normal Phenotype and Abolishedβ-amyloid Generation [210]
RR	March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 3d Ed., pp. 380-381 Aliphatic Nucleophilic Substitution [729]
RR	Martin et al., Tetrahedron Letters, 1998, 39, pp. 15171520 Application of Almez-Mediated Amidation Reactions to Solution Phase Peptide Synthesis [540]
PR	Mashraqui et al., J. Am. Chem. Soc., 1982, 104, pp. 44614465 Cyclophanes. 14. Synthesis, Structure Assignment, and Conformational Properties of [2.2](2,5)Oxazolo- and Thiazolophanes [872]
RR	McLendon et al., <i>The FASEB Journal</i> , 2000, 14:15, pp. 23832386 Cell-Free Assays for Gamma-Secretase Activity [359]
RR	Miyaura et al., Chem. Rev., 1995, 95, pp. 24572483 Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds [720]
ER	Moersch et al., Synthesis, 1971, 12, pp. 647-649 The Synthesis of Alpha-Hydroxycarboxylic Acids by Aeration of Lithiated Carboxylic Acids in Tetrahydrofuran Solution [564]
KR	Murahashi et al., J. Org. Chem., 1992, 57:9, pp. 2521-2523 Ruthenium-Catalyzed Hydration of Nitriles and Transformation of δ-Keto Nitriles to Ene-Lactams [877]
1565	Norman et al., J. Med. Chem., 2000, 43, pp. 42884312 Structure-Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine Derivatives and Related Compounds as Neuropeptide Y5 Receptor Antagonists [867]
RR	Owa et al., J. Med. Chem., 1999, 42, pp. 37893799 Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle [866]
RP	Pirttila et al., Neuroscience Letter, 1998, 249, pp. 2124 Longitudinal Study of Cerebrospinal Fluid Amyloid Proteins and Apolipoprotein E in Patients with Probable Alzheimer's Disease [738]
RR	Reetz et al., Tetrahedron Letters, 30:40, pp. 54255428 Protective Group Tuning in the Stereoselective Conversion of α-Amino Aldehydes into Aminoalkyl Epoxides [884]
RR	Sabbagh et al., Alzheimer's Disease Review, 1997, 3, 1-19 β-Amyloid and Treatment Opportunities for Alzheimer's Disease [589]
RR	Sakurai et al., Chemical & Pharmaceutical Bulletin, 1993, 41:8, pp. 1378-1386 Studies of HIV-1 Protease Inhibitors, II, Incorporation of Four Types of Hydroxyethylene Dipeptide Isosteres at the Scissile Site of Substrate Sequences [549]
PR	Sakurai et al., Tetrahedron Letters, 1993, 34:10, pp. 5939-5942 A New Synthetic Route for the Gamma-Lactone Precursors of Hydroxyethylene Dipeptide Isosteres [563]

EXAMINER R

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw lin through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC:

′.				·	Ć
•	OCT	2	2	2001	
o					

Sheet 10 of 11

.....

RECE DEC 1

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USU1 Application Number

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: 16862

Sebti et al., Tetrahedron Letters, 1996, 37:36, pp. 6555-6556 Catalyse Heterogene de L'Hydratation des Nitriles en Amides par le Phosphate Naturel Dope par KF et le Phosphate Trisodique [878]
Selkoe, Nature, 1999, 399:6738, pp. A23-A31 Translating Cell Biology into Therapeutic Advances in Alzheimer's Disease [541]
Sclkoe, Neuron, 1991, 6:4, pp. 487-498 The Molecular Pathology of Alzheimer's Disease [742]
Seubert, et al., Nature, 9/1992, 359:6393, pp. 325327 Isolation and Quantification of Soluble Alzheimer'sβ-peptide from Biological Fluids [503]
Shearman et al., Biochemistry, 2000, 39, pp. 8698-9704 L-685, 458, an Aspartyl Protease Transition State Mimic, is a Potent Inhibitor of Amyloidβ-Protein Precursor γ-Secretase Activity [394]
Shibata et al., Tetrahedron Letters, 1997, 38:4, pp. 619-620 An Expeditious Synthesis of (2R,3S)-3-tertButoxycarbonylamino-1-isobutylamino-4-phenyl-2-butanol, a Key Building Block of HIV Protease Inhibitors [583]
Sinha, et al., Nature, 12/2/1999, 402:6761, pp. 537540 Purfication and Cloning of Amyloid Precursor Proteinβ-secretase from Human Brain [743]
Smith et al., Advanced Organic Chemistry - Reactions, Mechanisms and Structure, 2001, 5ed., Chpt. 19, pp. 1552-1554 Reduction of Carboxylic Acids and Esters to Alkanese [919]
Snyder et al., J. Am. Chem. Soc., Jan - Jun 1938, pp. 105-111 Organoboron Coimpounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids [873]
Thurkauf et al., J. Med. Chem., 1990, 33, 1452-1458 Synthesis and Anticonvulsant Activity of 1-Phenylcyclohexylamine Analogues [749]
Tucker et al., J. Med. Chem., 1992, 35:14, pp. 2525-2533 A Series of Potent HIV-1 Protease Inhibitors Containing a Hydroxyethyl Secondary Amine Transition State Isostere: Synthesis, Enzyme Inhibition, and Antiviral Activity [731]
Vassar et al., Science, 10/22/1999, 286:5440, pp. 735-741 β-Secretase Cleavage of Alzheimer's Amýloid Precursor Protein by the Transmembrane Aspartic Protease BACE [750]
Vazquez et al., J. of Med. Chem., 1995, 38:4, pp. 581-584 Inhibitors of HIV-1 Protease Containing the Novel and Potent &-Hydroxyethyl)sulfonamide Isostere [582]
Wang et al., Synlett, 6/2000, 6, pp. 902-904 Preparation of α-Chloroketones by the Chloroacetate Claisen Reaction [886]
Werner et al., Organic Syntheses, 1973, Collective Vol. 5, pp. 273-276 Cyclobutylamine* [752]
Wilgus, et al., Tetrahedron Letters, 1995, 36:20, pp. 3469-3472 The Acid-Catalyzed and Uncatalyzed Hydrolysis of Nitriles on Unactivated Alumina [880]
Yan et al., Nature, 12/1999, 402:6761, pp. 533-537 Membrane-anchored Aspartyl Protease with Alzheimer's Diseaseβ-secretase Activity [753]

	^				
EXAMINER	RIC	2000	DATE CONSIDERED	6-10-03	
EXAMINER: Initial if reference and not consid red. Include co	considered, py of this fo	whether or not citation rm for next communica	n is in conformance with MPEP 609; ation to the Applicant.	draw line through citation if no	ot in conformance

Date Mailed:

| Comparison of the content of the co



EXAMINER

Rayruf

DATE CONSIDERED

6-10-02